ANI Revenue Per Employee from 2010 to 2024
| ANIP Stock | USD 65.14 0.34 0.52% |
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI main balance sheet or income statement drivers, such as Depreciation And Amortization of 62.8 M, Interest Expense of 28.9 M or Selling General Administrative of 157.9 M, as well as many exotic indicators such as Price To Sales Ratio of 1.94, Dividend Yield of 0.0031 or PTB Ratio of 2.18. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
ANI | Revenue Per Employee |
About ANI Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ANI Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. ANI Pharmaceuticals investors use historical funamental indicators, such as ANI Pharmaceuticals's Revenue Per Employee, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in ANI Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ANI Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ANI Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ANI Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota. ANI Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 601 people.
Pair Trading with ANI Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with ANI Stock
| 0.91 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.71 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
| 0.75 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
Moving against ANI Stock
| 0.97 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.91 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.89 | ME | 23Andme Holding | PairCorr |
| 0.89 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.87 | VCYT | Veracyte Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of ANI Pharmaceuticals Correlation against competitors. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for ANI Stock analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.89) | Earnings Share 0.85 | Revenue Per Share 27.044 | Quarterly Revenue Growth 0.397 | Return On Assets 0.0372 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.